Arrhythmogenic right ventricular dysplasia/cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Medical Diagnostics

Background:

• Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic heart condition causing ventricular arrhythmias and right ventricular dysfunction.
• Accurate diagnosis is paramount for effective ARVD/C management.
• Current diagnostic practices may overemphasize MRI, neglecting established International Task Force criteria.

Purpose of the Study:

• To highlight the importance of International Task Force criteria for diagnosing ARVD/C.
• To emphasize the typical noninvasive and invasive diagnostic findings in ARVD/C.
• To guide treatment decisions, including ICD implantation and genetic screening.

Main Methods:

• Review of diagnostic criteria for ARVD/C.
• Discussion of noninvasive tests (ECG, echocardiogram) and invasive tests (RV angiogram, biopsy, EP study).
• Consideration of implantable cardioverter-defibrillator (ICD) indications and pharmacologic treatments (beta-blockers, ACE inhibitors).
• Emphasis on genetic screening for plakophilin-2 mutations.

Main Results:

• ARVD/C diagnosis requires adherence to International Task Force criteria.
• Patients typically present with abnormal ECG, echocardiogram, and ventricular arrhythmias.
• Invasive testing is recommended when noninvasive findings are suggestive.
• ICDs are indicated for syncope, sudden death, sustained ventricular arrhythmias, or specific ARVD/C evidence.
• Beta blockers and ACE inhibitors are recommended treatments.
• Plakophilin-2 mutation screening is beneficial for diagnosis and family management.

Conclusions:

• Correct diagnosis of ARVD/C hinges on International Task Force criteria.
• A comprehensive approach combining noninvasive, invasive, and genetic testing is essential.
• Timely ICD implantation and appropriate medical therapy improve outcomes for ARVD/C patients.